Key Highlights

  • Hydrix (ASX:HYD) reported AUD 2.8 million in September-quarter services revenue, up 11.6% year on year.
  • The services division recorded AUD 4.1 million in contract sales and appointed a US-based Business development executive.
  • The medical division secured a multi-year cardiac monitoring contract valued at about AUD 650,000.
  • The company ended the quarter with AUD 1.5 million in cash after AUD 1.1 million in net operating outflows.

Hydrix (ASX:HYD) provides engineering and product development services and commercialises medical technology. In a trading update released on 29 October 2026, it reported higher September-quarter services Revenue and disclosed a multi-year customer contract in Singapore. The company also outlined the cash effects of payment timing and several period-specific expenses.

Services revenue and the contract pipeline

Hydrix reported that services revenue of AUD 2.8 million was 28.1% above the preceding quarter and 11.6% above the September 2025 quarter. It disclosed AUD 4.1 million in contract sales for the division. The release presented contract sales separately from quarterly revenue and identified the work won as a source of activity for the engineering team. Hydrix appointed a vice-president of business development based in the United States. The company said the role would enable its team to engage directly with medical technology customers in that market.

Engineering activity during the quarter included a regulated medical robotics program. Hydrix said the work involved embedded electronics, software, systems integration and verification. The company cited the ramp-up of that regulated medical robotics program in its account of recent contract wins moving into engineering work during the period.

First regional cardiac monitoring sale

The medical division signed a multi-year contract to Supply a remote cardiac monitoring platform to the National Heart Centre Singapore. Hydrix valued the agreement at approximately AUD 650,000 and described it as its first commercial sale of the platform in the Asia-Pacific region. The company identified the hospital as a reference customer for future commercial activity. It listed Australia, Singapore and New Zealand among the markets in its regional medical sales plans. The figure announced in the release describes the multi-year contract value.

Customer receipts and the timing of payments

The company received AUD 2.5 million from customers and recorded net operating cash outflows of AUD 1.1 million. It reported a net cash financing outflow of AUD 300,000 and ended September with AUD 1.5 million in cash. Hydrix said some receipts had been delayed on projects where customers were raising funds for development or where contract payments were linked to project milestones. In the October release it anticipated those payments would be brought up to date in the December quarter. It did not give a separate amount for the delayed receipts.

The quarter also included payments related to the June Capital raising. Hydrix said the timing of Superannuation payments changed from quarterly to monthly from 1 July, resulting in two quarters of superannuation being paid during the September period. Management described the timing of these payments as a Factor in how much cash the group used.

Priorities across the business

Hydrix identified converting contracted work and sales opportunities into revenue as an immediate priority. It also reported delivery of an initial project milestone under a separate development contract and said four opportunities from a review of 12 were in active technical and market assessment. In medical technology, the company’s stated objective was to follow up its Singapore contract with further work across the region.

The September figures show higher engineering services revenue on both comparisons given in the release. The medical contract adds a separate multi-year agreement, while the company’s update on receipts links some expected December-quarter payments to customer funding or project milestones.